Elsevier

Leukemia Research

Volume 29, Issue 11, November 2005, Pages 1263-1269
Leukemia Research

Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs

https://doi.org/10.1016/j.leukres.2005.04.005Get rights and content

Abstract

Canine non-Hodgkin's lymphoma (NHL) is considered to be a good animal model for its human counterpart; nevertheless, comparative data on neoangiogenesis are completely lacking. The aim of this study is to investigate the levels of serum vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) 2 and 9 in lymphoma-affected dogs. Circulating levels of VEGF and both MMP 2 and 9 activities significantly correlate with the WHO substage b prognostic factor; moreover, VEGF at admission have an independent influence on the length of the disease free interval. As in humans, serum VEGF concentration and most likely also MMPs plasma activity have prognostic value in canine NHL spontaneous model.

Introduction

Neoangiogenesis is a tightly controlled phenomenon regulated by complex interactions of many different molecules. In recent years, evidence has accumulated which shows that abnormal angiogenesis, besides its well-known role in solid tumor growth and metastasis, is also critically involved in hematologic malignancies such as multiple myeloma (MM), leukemia, myelodisplastic syndromes (MDS) and non-Hodgkin's lymphoma (NHL) [1], [2]. Many authors have measured the circulating levels of angiogenic factors in patients affected by lymphoproliferative disorders with the aim of establishing their possible association with prognosis and outcome. Among pro-angiogenic molecules, VEGF and MMP 2 and 9 (gelatinases A and B) play a pivotal role in tumor-associated angiogenesis. VEGF circulating levels are increased in acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukaemia (CML), MDS, MM, NHL and Hodgkin disease (HD) [1], [2], [3]. Recently, either circulating VEGF and MMP 9 levels or the expression of MMP 9 has been further correlated with a poor prognosis, response to therapy, overall survival and/or event-free period in NHL-affected patients [4], [5], [6].

Human non-Hodgkin's lymphomas present overlapping features with canine lymphomas allowing the formulation of a comparative classification system [7], [8] and the consideration of canine NHL as spontaneous models for its human counterpart [9].

In the present study, serum VEGF concentration and plasma MMPs activity in lymphoma-affected dogs were evaluated in order to investigate their relevance as prognostic markers and to clarify the possible role of spontaneous canine lymphoma as an animal model in experimenting with antiangiogenic drugs.

Section snippets

Patients and samples

We retrospectively evaluated two cohorts of samples, 48 sera and 23 platelet poor citrated plasma (PPCP), in order to test VEGF concentrations and matrix metalloproteinase activity, respectively, at admission and before chemotherapy in 51 NHL affected dogs having stored samples available and which had been diagnosed at the University of Bologna Veterinary Teaching Hospital between January 2001 and August 2004. Twenty dogs were shared in both cohorts. As controls, an additional group of 16

Results

Forty-eight sera obtained from lymphoma-affected dogs at admission, and 16 samples of healthy blood donor dogs were assayed for VEGF concentrations. Lymphoma-affected dogs showed significantly (p < 0.001) higher values when compared to healthy dogs (Table 2). VEGF concentration levels were not statistically correlated with platelets counts (Spearman R = −0.22, p = 0.110). Twenty-three PPCP of lymphoma-affected dogs at admission and 16 healthy control dogs were assayed for MMP 2 and 9 activities (Fig.

Discussion

It has previously been reported by others that the preanalytical steps of blood collections and the type of specimen both influence the validity of circulating angiogenesis markers. Many of the pitfalls are addressed in detail elsewhere [14], [15], [16]. In brief, serum VEGF measurement is influenced mainly by the VEGF storage and release functions of platelets [17]. This fact has raised concerns about which is the most appropriate sample to better represent the real increase of serum

References (28)

  • T.M. Moeller et al.

    Angiogenesis in hematologic malignancies

    Ann Hematol

    (2001)
  • P. Salven

    Angiogenesis in lymphoproliferative disorders

    Acta Haematol

    (2001)
  • K. Sakata et al.

    Expression of matrix Metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma

    Cancer

    (2004)
  • B. Hazar et al.

    Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphoma

    Int J Clin Pract

    (2004)
  • Cited by (43)

    • Serum vascular endothelial growth factor in dogs with haemangiosarcoma and haematoma

      2014, Research in Veterinary Science
      Citation Excerpt :

      This kit has only recently become commercially available, and to our knowledge, there is only one study available in veterinary oncology using the same canine ELISA kit (Aresu et al., 2014). However, several studies have demonstrated increased serum VEGF levels in dogs with different tumour types using a human VEGF ELISA (Gentilini et al., 2005; Kato et al., 2007; Thamm et al., 2008). This ELISA is designed to measure VEGF 165 levels and its reliability in dogs has already been reported (Troy et al., 2006).

    • Expression of Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases and Vascular Endothelial Growth Factor in Canine Mast Cell Tumours

      2012, Journal of Comparative Pathology
      Citation Excerpt :

      It also stimulates abnormal angiogenesis in solid tumour growth and metastasis (Ribatti et al., 1999; Takanami et al., 2000; Elpek et al., 2001; Ranieri et al., 2002, 2003; Iamaroon et al., 2003; Kondo et al., 2006; Tuna et al., 2006). VEGF expression has been evaluated in canine mammary carcinoma (Restucci et al., 2002; Qiu et al., 2008), seminoma (Restucci et al., 2003), intracranial meningioma (Matiasek et al., 2009) and lymphoma (Gentilini et al., 2005; Wolfesberger et al., 2007, 2008). Crosstalk between VEGF and MMPs has recently been described: VEGF signalling via VEGFR-2 induces the expression of MMP-2, MMP-9 and MT1-MMP, which degrade the matrix to allow for endothelial sprouting (Funahashi et al., 2011).

    • Hematopoietic Tumors

      2012, Withrow and MacEwen's Small Animal Clinical Oncology: Fifth Edition
    • Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs

      2012, Research in Veterinary Science
      Citation Excerpt :

      We could not detect any significant relationship. Gentilini et al. (2005) reported that a high serum VEGF concentration at admission was negatively correlated with disease-free interval in lymphoma-affected dogs. No other immunohistochemical data exist with regard to the presence of VEGF in canine lymph node samples; therefore, we cannot compare our results with other veterinary studies.

    View all citing articles on Scopus
    View full text